Drug-induced erythroderma in patients with acquired immunodeficiency syndrome.
Acquired immunodeficiency syndrome
Drug eruption
Erythroderma
Modified severity-of-illness score for toxic epidermal necrolysis
Journal
World journal of emergency medicine
ISSN: 1920-8642
Titre abrégé: World J Emerg Med
Pays: China
ID NLM: 101549691
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
02
2021
accepted:
08
07
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
ppublish
Résumé
To explore the clinical manifestations, diagnosis, and treatment of patients with acquired immunodeficiency syndrome (AIDS) complicated with drug-induced erythroderma. The clinical data of 12 AIDS patients with drug-induced erythroderma in our hospital were retrospectively analyzed. The general information, offending medications, complications, modified severity-of-illness score for toxic epidermal necrolysis (SCORTEN) scores, and disease outcome spectrums were analyzed. Drug-induced erythroderma was mostly caused by antiviral drugs, antituberculosis drugs, antibiotics, traditional Chinese medicine, and immune checkpoint inhibitors. The spectrum of sensitizing drugs was broad, the clinical situation was complex, and infections were common. The affected areas were greater than 40% body surface area in all patients. The modified SCOTERN score averaged 3.01±0.99. All patients were treated with glucocorticoids, and nine patients were treated with intravenous immunoglobulin (IVIG) pulse therapy at the same time. The average time to effectiveness was 7.08±2.23 days, and the average hospital stay was 17.92±8.46 days. Eleven patients were cured, and one patient died of secondary multiple infections, who had a modified SCORTEN score of 5 points. The mortality rate in this study was 8.3%. The clinical situation of AIDS patients with drug-induced erythroderma in hospitalized patients is complex and the co-infection rate is high. The use of modified SCORTEN score may objectively and accurately assess the conditions, and the use of glucocorticoid combined with IVIG therapy may improve the prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
To explore the clinical manifestations, diagnosis, and treatment of patients with acquired immunodeficiency syndrome (AIDS) complicated with drug-induced erythroderma.
METHODS
METHODS
The clinical data of 12 AIDS patients with drug-induced erythroderma in our hospital were retrospectively analyzed. The general information, offending medications, complications, modified severity-of-illness score for toxic epidermal necrolysis (SCORTEN) scores, and disease outcome spectrums were analyzed.
RESULTS
RESULTS
Drug-induced erythroderma was mostly caused by antiviral drugs, antituberculosis drugs, antibiotics, traditional Chinese medicine, and immune checkpoint inhibitors. The spectrum of sensitizing drugs was broad, the clinical situation was complex, and infections were common. The affected areas were greater than 40% body surface area in all patients. The modified SCOTERN score averaged 3.01±0.99. All patients were treated with glucocorticoids, and nine patients were treated with intravenous immunoglobulin (IVIG) pulse therapy at the same time. The average time to effectiveness was 7.08±2.23 days, and the average hospital stay was 17.92±8.46 days. Eleven patients were cured, and one patient died of secondary multiple infections, who had a modified SCORTEN score of 5 points. The mortality rate in this study was 8.3%.
CONCLUSIONS
CONCLUSIONS
The clinical situation of AIDS patients with drug-induced erythroderma in hospitalized patients is complex and the co-infection rate is high. The use of modified SCORTEN score may objectively and accurately assess the conditions, and the use of glucocorticoid combined with IVIG therapy may improve the prognosis.
Identifiants
pubmed: 34512827
doi: 10.5847/wjem.j.1920-8642.2021.04.008
pii: WJEM-12-299
pmc: PMC8390352
doi:
Types de publication
Journal Article
Langues
eng
Pagination
299-302Informations de copyright
Copyright: © World Journal of Emergency Medicine.
Déclaration de conflit d'intérêts
Conflicts of interests: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
Références
An Bras Dermatol. 2019 Jan-Feb;94(1):17-23
pubmed: 30726458
Arch Dermatol. 2012 Apr;148(4):543-4
pubmed: 22508885
Br J Dermatol. 2007 May;156(5):1083-4
pubmed: 17381452
Dermatopathology (Basel). 2019 Jun 26;6(2):111-125
pubmed: 31700852
Dermatol Clin. 2000 Jul;18(3):509-20, x
pubmed: 10943545
World J Emerg Med. 2017;8(1):65-67
pubmed: 28123624
Dermatol Ther. 2020 Nov;33(6):e14342
pubmed: 32979015
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):2066-2077
pubmed: 31912590
N Engl J Med. 1993 Jun 10;328(23):1670-4
pubmed: 8487826
Toxicology. 2005 Apr 15;209(2):165-7
pubmed: 15767030
J Burn Care Res. 2018 Jun 13;39(4):555-561
pubmed: 29789855
Arch Dermatol. 1973 Dec;108(6):788-97
pubmed: 4271796
J Burn Care Res. 2012 Nov-Dec;33(6):e295-308
pubmed: 22955159
Postgrad Med. 2005 Jan;117(1):49-51
pubmed: 15672891
Sci Rep. 2020 Jun 17;10(1):9774
pubmed: 32555205
Clin Dermatol. 1993 Jan-Mar;11(1):67-72
pubmed: 8339203
Int J Dermatol. 2021 May;60(5):e203-e205
pubmed: 33296075
Dermatol Clin. 2000 Jul;18(3):405-15
pubmed: 10943536
JAMA Dermatol. 2020 Dec 1;156(12):1294-1299
pubmed: 33084873